FOXO4-DRI (FOXO4-D-Retro-Inverso) record · updated 6h ago

Neuro & moodHealing & recoveryGrade C · preclinicalResearch use only

All 3 studies Jump to the evidence Compare

What is FOXO4-DRI (FOXO4-D-Retro-Inverso) used for?

FOXO4-DRI is a synthetic D-retro-inverso senolytic peptide designed to disrupt the FOXO4-p53 interaction and trigger selective apoptosis in senescent cells in preclinical longevity research.

Primarily researched for · Neuro & mood

Development stage

where FOXO4-DRI (FOXO4-D-Retro-Inverso) sits between preclinical work and regulatory approval

1Current
Preclinical
Animal / in-vitro work
2Not reached
Phase 1
Safety in humans
3Not reached
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.

Identity

NameFOXO4-DRI (FOXO4-D-Retro-Inverso)

Chain length—

Molecular weight5,358 Da

FormulaC228H388N86O64

Structure typeNot established

ClassLongevity

Research levelEmerging

Discovered byCurated master list · 2026

Mass and formula from PubChem CID 167312269. No verified residue count for this compound.

Pharmacology

Mechanism—

Route—

Half-life—

Time to peak—

Duration—

Extraction confidence—

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 14, 2026. How this works →

Research stats

Total studies3

Human / animal / cellular0 / 1 / 0

Highest trial phasePreclinical

Years covered2023–2026

Latest study1mo ago

Publication history

20232026

Research funding

137 NIH projects · $15.6M awarded · through FY2026

Public grants naming this compound. Funding is interest, not evidence.

Safety signals

FAERS reportsnone recorded

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 3 Semantic Scholar UniProt

Study register

3 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
Neoagarotetraose from Marine Red Algae Attenuates Hypertensive Vascular Remodeling by Targeting FoxO4 to Inhibit Mitochondrial Superoxide Generation. FindingNA4 lowered blood pressure in SHR after 4 weeks of oral administration at doses of 200 or 250 mg/kg/day.	Animal	—	Full text read0.70
FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting. FindingNot reported in abstract.	review	2023	Full text read0.80
FOXO family and neurodegenerative diseases: Mechanisms of action and therapeutic potential. TakeawayFOXO transcription factors play diverse roles in neurodegenerative diseases, but effective therapies targeting these pathways are still in early development stages.	review	2026	Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching FOXO4-DRI (FOXO4-D-Retro-Inverso) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much FOXO4-DRI (FOXO4-D-Retro-Inverso) is discussed should be drawn from it.